Phaseline

Companies › NextCell Pharma

NextCell Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ProTrans®
Allogeneic Wharton's jelly mesenchymal stromal cells
–Phase 1COVID-19 Acute Respiratory Distress SyndromeMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04896853ProTrans®Phase 1COVID-19 Acute Respiratory Distress SyndromeInfectious diseaseMar 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.